Search

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, announced the first patient dosing in Australia on December 30, [...]

Hansa Biopharma and Genethon, a company focusing on gene therapy research and development for rare genetic diseases, reported initiation of GNT-018-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome [...]

Hansa Biopharma and Genethon, a company focusing on gene therapy research and development for rare genetic diseases, reported initiation of GNT-018-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome [...]

Blue Lake Biotechnology, a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and [...]

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, [...]

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, [...]

Hansa Biopharma, a pioneering commercial-stage biopharmaceutical company, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced initiation of GNT-018-IDES, a phase [...]

Hansa Biopharma and Genethon, a company focusing on gene therapy research and development for rare genetic diseases, reported initiation of GNT-018-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome [...]

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced that the first participant has been vaccinated in a phase 2a clinical trial (NCT06582277) [...]

Biogen presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy. The results showed substantial reductions in proteinuria, [...]

2024 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Clinical Research - Clinical Trials and Studies are discussed [...]

LakeShore Biopharma announced that it has been granted approval for a Phase III clinical trial by the National Medical Products Administration, or NMPA, in China to explore the immunogenicity and [...]

Cyclacel Pharmaceuticals announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib, or [...]

Gilead Sciences, Inc. and Merck, known as MSD outside of the United States and Canada, announced new results from a phase 2 clinical study evaluating the investigational combination of islatravir, [...]

Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, announced that the US Food and Drug Administration (FDA) has granted fast track designation for its [...]

Kiromic BioPharma reported that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. The company said the [...]

Genentech, a member of Roche, announced topline results from the Phase III REGENCY study of Gazyva in people with active lupus nephritis. In the study, a higher proportion of people [...]

CD(Suzhou) Biopharma, a rapidly advancing clinical-stage biotech company, has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a [...]

Immix Biopharma announced the addition of three additional clinical trial sites for its U.S. relapsed/refractory AL amyloidosis clinical trial NEXICART-2. 'The newly added centers include some of the leading programs [...]

Palatin Technologies announced receipt of FDA correspondence confirming the acceptability of the protocols and endpoints for signs and symptoms of PL9643 Phase 3 pivotal clinical trials for dry eye disease. [...]

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a phase 1 trial with wet age-related macular degeneration (wAMD), [...]

Sutro Biopharma announced that REFRalphaME-L1, the global Phase 2 study of luveltamab tazevibulin for patients with non-small cell lung cancer whose tumor expresses Folate Receptor-alpha, has been initiated and is [...]

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, announced the completion of patient recruitment for its phase 2a clinical trial with AX-158, a [...]

Kiromic BioPharma reported interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel, the company's allogeneic, off-the-shelf, Gamma Delta T-cell, [...]

RedHill Biopharma announced the new publication of ground-breaking positive data showing that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective [...]

Sage Therapeutics (SAGE) and Biogen (BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor. [...]

GT Biopharma announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half [...]

Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy [...]

Kiromic BioPharma reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel, the Company's allogeneic, off-the-shelf, Gamma [...]

Palatin Technologies announced the initiation of a Phase 2 clinical study of bremelanotide, a melanocortin 4 receptor, co-administered with a phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction in [...]

Genentech, a member of the Roche, announced statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi in combination with gemcitabine and oxaliplatin versus Rituxan in [...]

2024 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Hansa Biopharma AB, ('Hansa' or the 'Company') (NASDAQ Stockholm: HNSA), announced recruitment [...]

OS Therapies, a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, reported a positive clinical update for AOST-2121 (NCT04974008), its ongoing Phase 2b clinical [...]

Two clinical trials have launched to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the [...]

Arbutus Biopharma announced new data from its Phase 2a clinical trial IM-PROVE I showing that imdusiran, the company's RNAi therapeutic, and 24 weeks of pegylated interferon alfa-2a, or IFN, a [...]

Cue Biopharma announced updated data from its ongoing Phase 1 trial evaluating its lead oncology asset from the CUE-100 series of biologics, CUE-101. The data will be presented in an [...]

Hansa Biopharma AB, (Hansa), a pioneering commercial-stage biopharmaceutical company, announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal phase 3 open label, randomized, controlled [...]

Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate [...]

Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, announced topline results from its recently [...]

IMUNON announced that DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study with IMNN-101 in a seasonal Covid-19 vaccine. [...]